Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Organon & Co(OGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OGN
09/28/2026: OGN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Organon & Co is a pharmaceutical company that separated from Merck & Co. to focus on women's health, biosimilars, and established medicine brands. The company leverages a stable, cash-flow-generating portfolio to support its dividend and fund strategic, bolt-on acquisitions. While it holds a leading position in specific areas like reproductive health, it faces significant risks from its high debt burden and competitive pressure from generic and biosimilar rivals. The stock is generally seen as a fit for value and dividend-focused investors seeking steady income over rapid growth. Investors should monitor the company's ability to reduce debt, successfully integrate new acquisitions, and navigate patent-related revenue challenges.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company relies more on established, mature assets than high-growth novel drug innovation. |
| Momentum investor | Weak fit | The stock has historically lacked the sustained upward price momentum typically sought by this style. |
| Value investor | Strong fit | The company trades at a relatively low valuation multiple reflecting its mature portfolio. |
| Dividend investor | Strong fit | The company maintains a reliable dividend policy supported by stable cash flows. |
| Low-risk investor | Mixed fit | While established, the high debt load and industry regulatory risks introduce volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Pharmaceutical sector stocks are sensitive to news regarding clinical trials and drug pricing. |
| Valuation risk | Low | The stock is currently priced to reflect modest growth expectations rather than high-growth premiums. |
| Competition risk (Generic and Biosimilar) | High | Entry of lower-cost competitors threatens to erode market share of key established products. |
| Business quality | Medium | The company manages a portfolio of mature products, which provides stability but limited long-term upside. |
| Dividend income | Medium | Sustainability depends on continued cash flow generation in the face of patent cliffs. |
| Execution risk | Medium | Success relies on the ability to integrate acquisitions and optimize a global supply chain. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 40.5% | Avg. Invested days 57 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.61B USD | Price to earnings Ratio 17.6 | 1Y Target Price 11.25 |
Price to earnings Ratio 17.6 | 1Y Target Price 11.25 | ||
Volume (30-day avg) 2.9M shares | Beta 1.52 | 52 Weeks Range 5.67 - 13.79 | Updated Date 09/27/2026 |
52 Weeks Range 5.67 - 13.79 | Updated Date 09/27/2026 | ||
Dividends yield (FY) 0.58% | Basic EPS (TTM) 0.78 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Women's Health | Contraceptives like Nexplanon and fertility drugs like Follistim. | This is the primary growth driver focusing on long-term health solutions for women. |
| Established Brands | Cardiovascular, respiratory, and pain management medications. | This segment provides steady, predictable cash flow to fund dividends and new investments. |
| Biosimilars | Lower-cost versions of complex biologic drugs. | These products compete on price in large, established therapeutic markets. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 17.6 | Forward PE 5.09 | Enterprise Value 11.03B | Price to Sales(TTM) 0.59 |
Enterprise Value 11.03B | Price to Sales(TTM) 0.59 | ||
Enterprise Value to Revenue 1.8 | Enterprise Value to EBITDA 8.4 | Shares Outstanding 262.61M | Shares Floating 242.99M |
Shares Outstanding 262.61M | Shares Floating 242.99M | ||
Percent Insiders 0.46 | Percent Institutions 84.81 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Organon & Co
Exchange NYSE | Headquarters Jersey City, NJ, United States | ||
IPO Launch date 2021-06-02 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 10000 | Website https://www.organon.com |
Full time employees 10000 | Website https://www.organon.com | ||
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.